CTFH and Insilico Collaborate on Accelerating First-in-class Therapeutics Using AI
Research Collaboration Highlights
- The collaboration aims to accelerate drug discovery and development with an AI-enabled platform for triple-negative breast cancer;
- CTFH is one of the top pharmaceutical companies in China focused on innovative drug discovery and development, with a strong internal R&D team and integrated R&D capabilities;
- The project value is up to $200 million, including an upfront payment, milestone payments, and royalties based on the net product sales;
- CTFH has achieved significant milestones in first-in-class drug development. With this partnership, CTFH will generate novel molecules with specified properties using Insilico's next-generation AI platform;
- This partnership will speed up the R&D process, reduce the cost and ultimately benefit the patients;
HONG KONG, and NANJING, CHINA - October 9, 2019 (12PM London time) - Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program research collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. ("CTFH"), taking on previously undruggable targets. Insilico Medicine will be eligible to receive up to $200 million for the achievement of milestone payments and royalties based on the net sales on the products from the collaboration. This partnership is expected to accelerate drug discovery and development with an AI-enabled platform for triple-negative breast cancer.
CTFH is an active adopter of state-of-the-art technologies and has achieved significant milestones in first-in-class drug development. Wenyu Xia, General Manager of CTFH, said: "We are very pleased to establish the partnership with Insilico Medicine, entering the new era of AI-enabled drug development. We look forward to a long-term partnership with Insilico Medicine. As the premier AI drug discovery company in the industry, Insilico Medicine has demonstrated capabilities to generate novel molecules with specified properties using its next-generation AI platform. We believe that this collaboration will speed up the R&D process, reduce the cost and provide greater benefits to patients."
Last month, Insilico Medicine published a landmark paper in Nature Biotechnology, demonstrating the application of its generative tensorial reinforcement learning systems in the generation of novel molecules for simple kinases in 46 days, including experimental validation. It also announced a $37 million round led by prominent biotechnology and AI investors.
MORE IN ITECHPOST
How Does Uber's New Hourly Function Work? Will a Rider Still Pay $50 For Shorter Trips? All FAQs Answered!
Uber now lets riders pay an hourly rate for a multi-stop trip. But where did it come from and why are they doing it? So many questions we'd like to ask!
Benefits of LED Grow Lights for Your Indoor Plants
There has been a surge in the number of growers cultivating indoor crops. Some turn to indoor farming in areas like cities, where there are almost no green spaces. Growing indoors takes advantage of otherwise wasted space and makes it possible for anyone to create an indoor garden.
Darkest Dungeon Is Celebrating Its New DLC With A Free Weekend: Here Are Some Tips To Help You Out!
Red Hook Studio's Darkest Dungeon has had a new DLC released on Steam and with it a free weekend. Grab the PvP game and try it out after reading these tips on how you can play the game the best you can.
[Spoiler Alert] Jurassic World 3: Will the Original Cast Be Back?
Jurassic World III is on its way and if you're wondering if you're expecting everything to be the same, you might be surprised. A source stated that the former cast of the Jurassic Park movie trilogy would be reprising their roles in Jurassic World: Dominion.